Local immunomodulation for cancer therapy: Providing treatment where needed

OncoImmunology

Volumn 2, Issue 11, 2013, Pages

  Fransen, Marieke F ^a   Ossendorp, Ferry ^a   Arens, Ramon ^a   Melief, Cornelis J M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISA Pharmaceuticals   (Netherlands)

Author keywords

Abscopal effect; CTLA 4; Immunomodulating; Local treatment; Side effects

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; COLITIS; DERMATITIS; DRUG EFFICACY; HUMAN; HYPOPHYSITIS; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; LOW DRUG DOSE; LYMPH NODE; METASTATIC MELANOMA; NEOPLASM; NONHUMAN; PHOTON THERAPY; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84892421320     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26493     Document Type: Article

References (10)

1. Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 2008; 223:143-55; PMID:18613834; http://dx.doi.org/10.1111/j.1600-065X.2008.00639.x.
2. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006; 6:659-70; PMID:16932751; http://dx.doi. org/10.1038/nri1919.
3. Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010; 22:215-22; PMID:20207124; http://dx.doi.org/10.1016/j.coi.2010.02.006.
4. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011; 17:2270-80; PMID:21389097; http://dx.doi.org/10.1158/1078-0432.CCR-10-2888.
5. Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ. Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects. Clin Cancer Res 2013; Forthcoming; PMID:23788581; http://dx.doi.org/10.1158/1078-0432CCR-12-0781.
6. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123:2447-63; PMID:23728179; http://dx.doi. org/10.1172/JCI64859.
7. Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 2008; 57:1263-70; PMID:18236040; http://dx.doi. org/10.1007/s00262-008-0451-3.
8. Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol 2013; 25:182-90; PMID:23706598; http://dx.doi.org/10.1016/j.smim.2013.04.008.
9. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med 2010; 363:2434-43; PMID:21158659; http://dx.doi.org/10.1056/NEJMra0912273.
10. Kroemer G, Zitvogel L. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 2012; 1:407-8; PMID:22754758; http://dx.doi.org/10.4161/onci.20074.